Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain zaps may wake up coma patients – early trial launches

NCT ID NCT07213869

Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a gentle, non-invasive brain stimulation technique called alpha tACS can improve consciousness in people who have been in a vegetative or minimally conscious state for 3–12 months after a traumatic brain injury. Five adults will each receive alternating two-week periods of stimulation and no stimulation over three months. The goal is to see if the stimulation leads to measurable improvements in awareness and brain activity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial alternating current stimulation (tACS)
What this could lead to
If it works, this could point toward a new non-drug treatment to help people with disorders of consciousness regain awareness.
What could go wrong
This is a very early, tiny study (only 5 people) with no control group. The results may not apply to others, and the treatment may show no clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 5 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 70 years * Persistent disorder of consciousness (vegetative state/unresponsive wakefulness syndrome or minimally conscious state) according to the Coma Recovery Scale-Revised (CRS-R), lasting 3 to 12 months after traumatic brain injury at the time of the inclusion * No evidence of exit from minimally conscious state (eMCS) according to Coma Recovery Scale-Revised (CRS-R) Exclusion Criteria: * Active epilepsy or major pre-existing central nervous system disorders * Craniectomy without bone flap replacement, non-healed scalp lesions, intracerebral metallic implants (except titanium), or implanted electronic devices (e.g., pacemaker) * Contraindications to MRI (non-compatible devices, metallic fragments, recent tattoos, etc.) * Pregnant or breastfeeding women * Persons deprived of liberty, under psychiatric care, or not affiliated with a social security/health insurance system

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Disorder of consciousness are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Brain Injuries, Traumatic Consciousness Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Disorder of consciousness

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Post-Intensive Care Neurorehabilitation Unit (Service de Reeducation Post-Reanimation) in Pierre Wertheimer Neurologic Hospital

    Bron, 69029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.